Subcutaneous specific immunotherapy (SCIT) added to omalizumab in severe allergic asthma patients -efficacy and safety M.Christopoulou, J.Moisidis, L.Panteli and A.Christopoulos Asthma Clinics Private outpatient clinic Patras/Greece
A. Christopoulos (Patras, Greece), M. Christopoulou (Patras, Greece), L. Panteli (Patras, Greece), I. Moisidis (Patras, Greece), I. Christopoulos (Patras, Greece)
Source: International Congress 2022 – Asthma treatment: real-world studies and other diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Christopoulos (Patras, Greece), M. Christopoulou (Patras, Greece), L. Panteli (Patras, Greece), I. Moisidis (Patras, Greece), I. Christopoulos (Patras, Greece). Subcutaneous specific immunotherapy (SCIT) added to omalizumab in severe allergic asthma patients -efficacy and safety M.Christopoulou, J.Moisidis, L.Panteli and A.Christopoulos Asthma Clinics Private outpatient clinic Patras/Greece. 1328
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|